key: cord-0953279-28x4eeuk
authors: Ricco, Matteo; Ranzieri, Silvia
title: BCG vaccination and COVID-19: Was flattening the curve just an illusion?
date: 2021-02-05
journal: Infect Dis Now
DOI: 10.1016/j.idnow.2021.02.003
sha: 82fc9fc882d38d559c2f0b2e7af7b94582c1131e
doc_id: 953279
cord_uid: 28x4eeuk

nan

During the early stages of the ongoing SARS-CoV-2 pandemic, some reports hinted at a "protective" effect of BCG vaccination regarding COVID-19, mainly in terms of avoided mortality (1, 2) . As a result, BCG vaccination emerged as being possibly instrumental in "flattening" the curves of the pandemic.

However, in a previous systematic review, we suggested that initial reports may have been "distorted" by the diachronous nature of the pandemic, of which the early stages strongly depended on the spreading of single outbreaks, which in turn were the eventual consequence of separate, even serendipitous events (3) . While Europe is faced with a sustained resurgence of SARS-CoV-2 infection, it is reasonable to surmise that initial differences may have been leveled out, allowing more consistent comparison between various countries, particularly when dealing with ecological factors such as BCG vaccination rates.

J o u r n a l P r e -p r o o f Therefore, with the aim of assessing the actual effect of BCG vaccination rates on SARS-CoV-2 incidence rates and mortality, we retrieved official data on 47 European Countries from the ECDC "COVID-19 situation update for the EU/EEA" (http://ecdc.europa.eu/en/cases-2019ncov-eueea) in the 01/03/2020-14/12/2020 timeframe. Available data included daily notification rates on new COVID-19 cases and deaths. Respective 7-day moving average for notification of incident cases and 14-day moving average for death cases were calculated accordingly. As BCG vaccination policies across European countries have been and remain quite heterogeneous (4), we utilized 12 th month vaccination coverage 1980-2019 from WHO/UNICEF (https://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoverageb cg.html) as a proxy, which was then codified as dummy variable: 0 for countries without any previous vaccination policy or discontinuing mass vaccination before 1990; 1 for BCG vaccination rates ≤ 80%, 2 for rates 80% to 89.9%, 3 for rates 90 to 94.9%, 4 for rates ≥ 95%.

Eventual estimates were then included as outcome variables of two distinctive regression models that were assumed as explanatory variables: BCG rate, population density, share of the general population aged 60 years or older, and two synthetic indices represented by the Gini coefficient and the Human Development Index (HDI) (5) . The aforementioned factors were retrieved from the Eurostat database (https://ec.europa.eu/eurostat/). Gini Coefficient is a measure of statistical dispersion designed to represent income inequality or wealth inequality within a nation. HDI is a composite statistical index of life expectancy, education, and per capita income. A summary of raw data is reported in Appendix 1.

Notification rates were not correlated with BCG rates or economic and demographic indices, nor, as shown in Table 1 , was BCG rate an effective predictor for either incident cases (Beta Our estimates are affected by significant limits. First, not only are European policies on BCG heterogenous, but also, the reporting of corresponding vaccination rates is often inconsistent (4) . As a result, we were forced to approximate, referring to a proxy rather than to actual vaccination rates. Second, notification rates on COVID-19 are characterized by significant heterogeneities, with resultingly uncertain estimates (6) . Third, different European countries applied mitigation measures that were heterogenous in terms of timing, scope and means (3, 6) . Such factors are essentially qualitative, and decidedly elusive in terms of statistical modelling. Lastly, European countries are highly variable in terms of ethnographic composition; as a result, background genetic factors can hardly be ruled out by means of ecological study (3) .

To conclude, our analyses suggest that the effects of BCG on the ongoing dynamics of the SARS-CoV-2 pandemic are very difficult, if not impossible to ascertain,. Even though the role of BCG-elicited "trained immunity" (i.e. enhanced reactivity of the innate immune system by means of increased secretion of pro-inflammatory cytokines) in COVID-19 has not been clearly ruled out, there is no evidence that BCG may protect people against SARS-CoV-2 infection (1-3), and there is no evidence justifying recommendation of BCG vaccination as a means of preventing COVID-19.

Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article. The facts, conclusions, and opinions stated in the article represent the authors' research, conclusions, and opinions, and are believed to be substantiated, accurate, valid, and reliable. However, as this article includes the results of personal research of the authors, presenting correspondent, personal conclusions, and opinions, parent employers are not forced in any way to endorse or share its content and its potential implications.

BCG Vaccination and mortality of covid-19 across 173 countries: An ecological study

The association of

Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination: a robust ecological evaluation using unsupervised machine learning

Stop playing with data: There is no sound evidence that bacille calmette-guérin may avoid SARS-CoV-2 infection for now

BCG) immunisation in Europe -A ptbnet survey and review of current guidelines

Social determinants of pulmonary tuberculosis in Brazil: an ecological study

Mitigation Policies and COVID-19 -Associated Mortality -37 European Countries